{"prompt": "['Committee.-A: interim analysis will be conducted to support a planned regulatory filing for FDC,', 'which will consist of a subset of the analyses planned for the primary analysis. The results of this', \"interim analysis will be evaluated by a Sponsor's Internal Monitoring Committee. Further details\", 'will be specified in the Statistical Analysis Plan.', '9.4', 'ADMINISTRATIVE STRUCTURE', \"If an interim safety analysis is conducted, the Sponsor's Internal Data Monitoring Committee\", \"will -evaluate the results.-Th results of the interim analysis will be evaluated by a Sponsor's\", 'Internal Monitoring Committee.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '6 / Protocol MO40628, Version 2']['Appendix 1', 'Schedule of Activities', 'End of', 'Treatment Continuation', 'Follow-up', 'Screening', 'Baseline', 'Treatment Cross-over Period', 'Treatment', 'Period [c]', 'Period [a]', 'Visit [b]', '15', '11', '1', '2', '3', '4', '5', '6', '7', '(or last', 'Study Cycle', '[d]', 'treatment', 'cycle) [e]', '28 days', 'Day', '-28 to -1', '-7 to -1', '1', '1', '1', '1', '1', '1', '1', '1', '1', 'from last', 'study dose', 'Adverse events [p]', '*', '*', '*', '*[p]', 'Adverse events [p]', 'X', 'x', 'Collected on an ongoing basis', 'x [p]', 'Concomitant medication [q]', '*', '*[q]', 'Concomitant medication [q]', 'X', 'Collected on an ongoing basis', 'x [q]', 'Notes Unless otherwise specified, assessments should be performed within three days of the scheduled visit. On treatment days, all assessments should be', 'performed prior to dosing, unless otherwise specified. For all protocol-mandated study visits, a time window of + 3 days is allowed. If a protocol mandated', 'study', 'visit coincides with a holiday and/or weekend that preclude the visit, the visit should be scheduled on the nearest following feasible', 'date.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '7/ Protocol MO40628, Version 2']['a. Either pertuzumab and trastuzumab FDC SC or P+H IV will be selected by the patient for study treatment during the Treatment Continuation Period.', 'During this period, pertuzumab and trastuzumab FDC SC or P+H IV will be administered for the number of 3-weekly cycles', 'calculated', 'based', 'on', 'the', 'number of Perjeta and Herceptin cycles received as neoadjuvant treatment prior to study entry and P+H IV and pertuzumab', 'and', 'trastuzumab', 'FDC', 'SC', 'cycles (six total cycles) received during the Treatment Cross-over Period. A total of 18 cycles of anti-HER2 treatment should be administered', 'for', 'EBC', 'treatment unless disease recurrence, unacceptable toxicity or patient withdrawal from treatment necessitates early cessation of treatment. No specific', 'investigations are required per protocol for Cycles 8-10 and Cycles 12-14 during the Treatment Continuation Period, although the PI may perform safety laboratory', 'assessments or other tests per institutional practice (these results are not required to be reported in the eCRF). However, information on treatment', 'administration', 'will', 'be collected, and new or worsened clinically significant abnormalities should be recorded as AEs on the Adverse Event eCRF.', 'n. Haematology: haemoglobin, total WBC, ANC / neutrophils, platelet count. Limited biochemistry: alkaline phosphatase; AST; ALT; LDH;', 'total', 'bilirubin;', 'creatinine. Albumin should be measured at Screening for determining patient eligibility. Bilirubin fractions (direct and indirect) must be included if', 'total', 'bilirubin', 'is greater than ULN. During the treatment period, bloods for haematology / biochemistry may be taken within three days prior to study treatment', 'administration.', 'o. Pregnancy testing is only required for women of childbearing potential: A woman of childbearing potential is defined as: post-menarchal, has not reached a', 'post-menopausal state (post-menopausal defined as 12 continuous months of amenorrhea with no identified cause other than menopause), and has', 'not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local', 'guidelines', 'or', 'requirements. For a all women of childbearing potential, Ppregnancy tests must be performed via serum \u00df-human chorionic gonadotropin', '(HCG) at baseline within seven days prior to first study treatment administration. Urine pregnancy tests should be repeated during the', 'Treatment', 'Cross-', 'over and Treatment Continuation Periodswithin seven days prior to every three treatment cycles-starting at Cycle 4, Cycle 7, Cycle', '11', 'and', 'Cycle', '15', '(or', 'at', 'last treatment cycle), (and as clinically indicated), with results available prior to study treatment administration, as well as at the', 'End', 'of', 'Treatment', 'Visit', 'and', 'at the Follow-up Visit until seven months after discontinuation of study treatment. Any positive urine pregnancy test must be confirmed with a serum', '\u00df-HCG test.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '8 / Protocol MO40628, Version 2']\n\n###\n\n", "completion": "END"}